Sign in to view content

Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial

Philip J. Ferrone, MD, FASRS

Video
Published 2019

Phillip J. Ferrone, MD

AMD Neovascular Part I Symposium

Related

Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting
Marko Lukic, MD PhD FEBO FASRS
On Demand Cases, Courses, and Papers
2019
Higher-Order Optical Coherence Tomography Fluid Burden Assessment: Analysis From the OSPREY Trial
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2019
Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019

Category: AMD-Neovascular

See more